At a glance
- Note: These files are not yet 508.
- Slides will be added as they become available.
April 15, 2025
Welcome & Introductions
Introduction
Dr. Keipp Talbot
Dr. Melinda Wharton
Mpox Vaccine
Dr. Faisal Minhaj
Presentation on immunogenicity and safety of JYNNEOS in 12-17 year olds
Dr. Buddy Creech
EtR for JYNNEOS in outbreaks
EtR for JYNNEOS due to the 2022 global outbreak
Dr. Faisal Minhaj
Lyme Disease Vaccine
Dr. Grace Marx
Influenza Vaccines
Dr. Jamie Loehr
Influenza vaccine effectiveness update
Dr. Aaron Frutos
Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza, California, October 2024 – January 2025
Dr. Sophie Zhu
Dr. Joshua Quint
FluMist for self or caregiver administration
Dr. Allyn Bandell
COVID-19 Vaccine
Dr. Robert Schechter
Moderna mRNA-1283 COVID-19 vaccine
Dr. Bishoy Rizkalla
Epidemiology and risk factors for COVID-19 hospitalizations
Dr. Fiona Havers
Dr. Ruth Link-Gelles
Workgroup considerations for use of 2025-2026 COVID-19 vaccines
Dr. Lakshmi Panagiotakopoulos
Pneumococcal Vaccines
Workgroup Next Steps and Proposed Work Plan
Dr. Miwako Kobayashi
Human Papillomavirus (HPV) Vaccines
Dr. Oliver Brooks
Update on literature related to reduced number of doses for HPV vaccination
Dr. Carla DeSisto
Dr. Ruanne Barnabas
Ms. Cassandra Pingali
Modeling of reduced number of doses for HPV vaccination series
Dr. Jane Kim
Modified EtR: wording of the age for routine HPV vaccination
Dr. Ruth Stefanos
Workgroup next steps and considerations
Dr. Lauri Markowitz
Cytomegalovirus (CMV) Vaccines
Dr. Denise Jamieson
CMV and cCMV epidemiology and disease burden
Dr. Tatiana Lanzieri
CMV vaccine safety and immunogenicity data
Dr. Robert Paris
Initial workgroup considerations for CMV vaccine policy
Dr. Tatiana Lanzieri
U.S. Measles Update
Dr. David Sugerman
April 16, 2025
Welcome & Introductions
Introduction
Dr. Keipp Talbot
Meningococcal Vaccines
Dr. Jamie Loehr
GSK pentavalent vaccine: review of EtR and workgroup considerations
Dr. Sarah Schillie
Updates to Meningococcal vaccines VFC resolution
Dr. Jeanne Santoli
Introduction to MenQuadfi label change for infants
Dr. Sarah Schillie
MenQuadfi in infants: safety and immunogenicity
Dr. Rachel Dawson
Workgroup considerations regarding MenQuadfi in infants
Dr. Sarah Schillie
Respiratory Syncytial Virus (RSV) Vaccines - Adults
Dr. Albert Shaw
Dr. Frances Priddy
Manufacturer Presentation: Arexvy (GSK) 36-Month Re-Vaccination
Dr. Susan Gerber
Economic Analysis of Adult RSV Vaccination, including benefits and risk discussion
Dr. Ismael Ortega-Sanchez
Comparison of Economic Analyses of Adult RSV Vaccination
Dr. Ismael Ortega-Sanchez
Dr. Diya Surie
Dr. Michael Melgar
Dr. Diya Surie
Chikungunya Vaccines
Dr. Edwin Asturias
EtR for use of virus-like particle chikungunya vaccine among adolescent and adult travelers
Dr. Susan Hills
EtR for use of virus-like particle chikungunya vaccine among laboratory workers
Dr. Erin Staples
Dr. Susan Hills
Dr. Erin Staples
Dr. Susan Hills
Dr. Dana Meaney-Delman
Respiratory Syncytial Virus (RSV) Immunizations- Maternal/Pediatric
Dr. Helen Chu
Ms. Danielle Moulia
Dr. Jefferson Jones